Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephri...
December 01 2017 - 9:00AM
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”)
announced today the acceptance of a presentation entitled “Human
Factors Study of A Newly Approved Epinephrine Prefilled Syringe
(Symjepi) for the Emergency Treatment of Allergic Reactions (Type
I) Including Anaphylaxis”. The presentation will be for the
American Academy of Allergy, Asthma, and Immunology (AAAAI) joint
congress with the World Allergy Organization and will be held in
Orlando, Florida on March 3, 2018. This premier annual
educational event draws thousands of healthcare professionals
including allergists, immunologists and other medical specialists.
Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi
was studied in trained and untrained adults, adolescents and
caregivers. The results definitively showed Symjepi to be an
easy to use, small and intuitive device.” Dr. Ronald Moss,
Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For
a layperson, treatment of anaphylaxis with a simple non-threatening
device is critical to successful use.” The presentation will
focus on the successful human factors study utilizing Symjepi.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company focused on developing and commercializing
products in the therapeutic areas of respiratory disease and
allergy. The company’s first product, Symjepi (epinephrine)
Injection 0.3mg, was approved in June 2017 for use in the emergency
treatment of acute allergic reactions, including anaphylaxis.
Adamis’ product pipeline includes HFA metered dose inhaler and dry
powder inhaler products for the treatment of bronchospasm and
asthma. The Company’s U.S. Compounding, Inc. (USC) subsidiary,
which is registered as a drug compounding outsourcing facility
under Section 503B of the U.S. Food, Drug & Cosmetic Act and
the U.S. Drug Quality and Security Act, compounds sterile
prescription drugs, and certain nonsterile drugs, to patients,
physician clinics, hospitals, surgery centers and other clients
throughout most of the United States.
Adamis Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the status of anticipated presentations by the company
at upcoming conferences; the company's beliefs concerning the
ability of its products and product candidates to compete
successfully in the market; the company’s beliefs concerning the
results of studies relating to Symjepi and user perceptions of
Symjepi; and the company's beliefs concerning the safety and
effectiveness of its products and product candidates. These
statements are only predictions and involve known and unknown
risks, uncertainties and other factors, which may cause Adamis'
actual results to be materially different from those contemplated
by these forward-looking statements. Certain of these risks,
uncertainties, and other factors are described in greater detail in
Adamis’ filings from time to time with the SEC, which Adamis
strongly urges you to read and consider, all of which are available
free of charge on the SEC's web site
at http://www.sec.gov. Any forward-looking statement in
this press release speaks only as of the date on which it is
made. Except to the extent required by law, Adamis expressly
disclaims any obligation to update any forward-looking
statements.
Contacts: Mark Flather Senior Director,
Investor Relations& Corporate Communications Adamis
Pharmaceuticals Corporation (858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024